We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market this year for leukocyte adhesion deficiency-type I (LAD-I), hemophilia B, and chronic obstructive pulmonary disease (COPD).
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- A spotlight on the treatment landscape and pipeline for Duchenne muscular dystrophy (DMD), and an overview of potential combination influenza and COVID vaccines.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
